Arcturus Therapeutics Holdings (ARCT) Share-based Compensation (2018 - 2026)

Arcturus Therapeutics Holdings has reported Share-based Compensation for 9 years, with the latest figure at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 35.08% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $23.1 million (down 33.25% YoY), and the FY2025 full-year result was $25.4 million, down 33.12% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.3 million, down from $6.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $10.1 million in Q1 2024, with the low at $4.3 million in Q1 2026.
• Historically, Share-based Compensation has averaged $7.8 million across 5 years, with a median of $8.2 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 37.35% — and 2025, when it tumbled 39.65%.
• Arcturus Therapeutics Holdings' Share-based Compensation stood at $6.5 million in 2022, then soared by 34.99% to $8.8 million in 2023, then grew by 1.91% to $9.0 million in 2024, then decreased by 24.11% to $6.8 million in 2025, then sank by 36.56% to $4.3 million in 2026.
• The last three Share-based Compensation figures came in at $4.3 million (Q1 2026), $6.8 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.